Glenmark conferred with Best Biotech New Molecular Entity Patent award

New Drug Approvals

GLENMARK PHARMA

IDMA best biotech NEW MOLECULAR ENTITY patent award to Glenmark

YEAR 2012-2013 YEAR in Mumbai India

PATENT  US 8236315

GLENMARK PHARMACEUTICALS, S.A., SWITZERLAND

INVENTORS

Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin BertschingerALSO PUBLISHED ASCA2712221A1, CN101932606A,EP2245069A1, US20090232804,WO2009093138A1 Publication number US8236315 B2 Publication type Grant Application number US 12/358,682 Publication date 7 Aug 2012 Filing date 23 Jan 2009 Priority date 23 Jan 2008

USPTO, USPTO Assignment, Espacenet, US 8236315

The present disclosure relates generally to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders. The humanized antibodies or binding fragments thereof specific for human vWF may comprise complementarity determining regions (CDRs) from a non-human antibody (e.g., mouse…

View original post 98 more words